Treatment of infections caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region

Clin Microbiol Infect. 2007 Feb;13(2):199-202. doi: 10.1111/j.1469-0691.2006.01591.x.

Abstract

This study reviewed 56 patients with significant metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa infections between May 2002 and March 2004 to identify features associated with mortality. Immunosuppression (p 0.002), bacteraemia (p 0.08) and inadequate antimicrobial therapy (p <0.001) were associated with death. Among those patients treated with adequate therapy, the use of multiple drug treatment regimens (two or three active agents) was associated with a non-significant two-fold increase in survival (p 0.45). Further prospective studies are warranted to determine the optimal treatment of MBL-producing P. aeruginosa infections.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Aztreonam / therapeutic use
  • Canada / epidemiology
  • Catchment Area, Health*
  • Colistin / therapeutic use
  • Cross Infection / epidemiology
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / mortality
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Pseudomonas aeruginosa / metabolism*
  • Retrospective Studies
  • Survival Rate
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases
  • Aztreonam
  • Colistin